Larry Keeley, an innovation expert and partner at Monitor, explains how Kodak’s famous failure to enter digital photography quickly can be a useful lesson for executives looking to innovate now. He writes that a new form of strategic thinking, convergences, “gives leaders a deeper sense of the interdependencies that connect firms, products, systems and services in new ecosystems” and reveals emerging opportunities, typically at the junction of new technologies and customer behaviors.

Determining and communicating the economic value of a product is one of the major strategic imperatives for the pharmaceutical industry as regulatory agencies move toward comparative effectiveness approaches and value-based pricing. Monitor’s Comparative Clinical and Economic Value (CCEV™) approach enables companies to apply economic-value-based thinking across the entire development, commercialization and health care delivery process.

At a time when the global life sciences and pharmaceutical industries are beset by major challenges, including patent cliffs, skyrocketing costs of drug approvals and failures in key trials, China is spending billions of dollars on life sciences initiatives. This report finds China poised to become the global leader in life science discovery and innovation within the decade.

The slowed growth experienced by the German medical devices market, a large, global industry with a history of innovation and profit, requires targeted and pragmatic responses from industry leaders. In this article, the authors explain how companies can use value-based pricing systems to optimize their bottom line and avoid being caught in the downward spiral that comes with reactionary price cutting.

In this article, Monitor’s Thomas Nagle and Lisa T. Thompson explain how companies can create profitable business models by integrating marketing and operations decision-making. In choosing revenue sources that leverage their strengths, and defining elements of sales that cause functional costs to vary, companies find growth.